Related Experiment Video
Updated: Aug 14, 2026
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Improving the selectivity of cancer treatments by interfering with cell response pathways
Giovanna Damia1, Massimo Broggini
1Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri, Via Eritrea 62, 20157 Milan, Italy.
Abstract:
The cellular response to the stress induced by treatment with anticancer agents is a key determinant of drug activity. A pivotal role in this response is played by checkpoint proteins that control the normal passage of cells through the cell cycle. There is evidence that cancer cells often have defects in one checkpoint control that makes them more vulnerable to inhibition of a second checkpoint, thereby enhancing the overall response to treatment. The G1 and G2 checkpoints are particularly crucial for the decision of a cell to arrest in the cell cycle after damage. The checkpoints are used to try to allow the repair of any damage, or to activate the apoptotic (programmed cell death) machinery. Inhibition of both G1 and G2 checkpoints in cancer cells is therefore likely to result in an induction of the death response in cancer cells. Similarly, an increasing knowledge of the molecular mechanisms that form the basis of apoptotic pathways has helped to define why cancer cells have a reduced propensity to undergo apoptosis following the activation of apoptotic inhibitory pathways or the inhibition of pro-apoptotic pathways. Therefore, the possibility to modulate these pathways is likely to result not only in the increased activity of anticancer agents, but also in an increase in their specificity.
Insights
Targeting cell cycle checkpoints and apoptosis pathways can enhance anticancer drug efficacy. Inhibiting both G1 and G2 checkpoints in cancer cells may induce programmed cell death, improving treatment outcomes.
Area of Science:
- Oncology
- Cell Biology
- Molecular Medicine
Background:
- Cellular stress response to anticancer agents is critical for drug efficacy.
- Checkpoint proteins regulate cell cycle progression and DNA damage repair.
- Cancer cells often exhibit defects in checkpoint controls, offering therapeutic vulnerabilities.
Purpose of the Study:
- To explore the role of cell cycle checkpoints (G1 and G2) in cancer cell response to treatment.
- To investigate the potential of inhibiting multiple checkpoints to enhance anticancer therapy.
- To understand the molecular mechanisms of apoptosis in cancer and its modulation.
Main Methods:
- Analysis of cellular responses to anticancer agents.
- Investigating the function of G1 and G2 checkpoints in cell cycle arrest and DNA repair.
- Examining the molecular pathways governing apoptosis in cancer cells.
Main Results:
- Inhibition of both G1 and G2 checkpoints in cancer cells is likely to induce programmed cell death.
- Defects in cancer cell checkpoints can increase vulnerability to combined checkpoint inhibition.
- Understanding apoptosis pathways reveals why cancer cells resist cell death.
Conclusions:
- Modulating cell cycle checkpoints and apoptosis pathways can increase anticancer agent activity and specificity.
- Targeting G1 and G2 checkpoints offers a promising strategy to enhance cancer treatment.
- Further research into apoptosis modulation could lead to more effective and targeted cancer therapies.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
10:46A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
Published on: September 13, 2022
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy